Intracellular accumulation, subcellular distribution and efflux of tilmicosin in swine phagocytes.
Tilmicosin is a semi-synthetic macrolide antibiotic, currently approved for veterinary use in cattle and swine respiratory disease. As the concentrations of tilmicosin are generally low in swine lung tissue, the interaction of tilmicosin with three types of swine phagocytes (monocyte-macrophages, alveolar macrophages, and neutrophils) was evaluated to provide an understanding of clinical efficacy. After incubation with radiolabelled tilmicosin, uptake was determined and expressed as the ratio of the intracellular (Ci) to the extracellular (Ce) drug concentration (Ci/Ce). Tilmicosin was avidly accumulated by the swine phagocytes (Ci/Ce 48-69 at 4 h incubation) with 51 to 85% localized in the lysosomes. Uptake was dependent on cell viability, temperature and pH, but was not influenced by the metabolic inhibitors, sodium cyanide or potassium fluoride. However, lipopolysaccharide (LPS) exposure increased tilmicosin uptake by the swine phagocytes. In neutrophils, upon removal of extracellular tilmicosin, 60% of the intracellular tilmicosin was effluxed within the first 30 min, but after 4 h of incubation in drug-free medium, 25% remained cell-associated. In contrast, after 4 h of incubation in drug-free medium, 60% and 45% of tilmicosin remained cell-associated, within alveolar macrophages and monocyte-derived macrophages, respectively. Tilmicosin uptake was observed to increase lysosomal enzyme (acid phosphatase, lysozyme and beta-glucuronidase) production. Finally, neutrophils were shown to transport and efflux bioactive tilmicosin in a test system measuring both neutrophil chemotaxis under agarose and a bioassay measuring inhibition of bacterial growth in the presence of antibiotic in agar. These in vitro interactions of tilmicosin with swine phagocytes suggest an integral role in effecting clinical efficacy.
Scorneaux
B
B
Animal science Research, Elanco Animal Health, Greenfield, IN 46140, USA. Scorneaux_Bernard@Lilly.com
Shryock
T R
TR
D000135:Acid Phosphatase / Q000378:metabolism; D000818:Animals; D000900:Anti-Bacterial Agents / Q000032:analysis / Q000378:metabolism*; D002470:Cell Survival; D002478:Cells, Cultured; D003470:Culture Media / Q000032:analysis; D005459:Fluorides / Q000494:pharmacology; D005966:Glucuronidase / Q000378:metabolism; D006863:Hydrogen-Ion Concentration; D008070:Lipopolysaccharides; D008247:Lysosomes / Q000187:drug effects* / Q000201:enzymology; D018942:Macrolides; D016676:Macrophages, Alveolar / Q000378:metabolism; D009000:Monocytes / Q000378:metabolism; D009504:Neutrophils / Q000378:metabolism; D010586:Phagocytes / Q000378:metabolism*; D017680:Potassium Compounds / Q000494:pharmacology; D012966:Sodium Cyanide / Q000494:pharmacology; D013347:Subcellular Fractions / Q000378:metabolism; D013552:Swine; D013696:Temperature; D015645:Tylosin / Q000031:analogs & derivatives* / Q000032:analysis / Q000378:metabolism
D000900:Anti-Bacterial Agents; D003470:Culture Media; D008070:Lipopolysaccharides; D018942:Macrolides; D017680:Potassium Compounds; C033320:potassium fluoride; D000135:Acid Phosphatase; D005966:Glucuronidase; D012966:Sodium Cyanide; D005459:Fluorides; C052319:tilmicosin; D015645:Tylosin